Table 2.
Meta-Analysis and TSA results of dorzagliatin for AEs.
| Outcome |
Dorzagliatin arm (events/total) |
Placebo arm (events/total) |
I2 | RR (95% CI) | TSA | Quality of evidence |
|---|---|---|---|---|---|---|
| Total AEs | 59/743 | 37/590 | 0 | 1.56 (1.06, 2.30) | No | Moderate |
| Serious AEs | 0/692 | 1/537 | 0 | 0.17 (0.01, 4.03) | No | Moderate |
| Hyperlipidemia | 3/692 | 1/537 | 0 | 1.80 (0.27, 12.18) | No | Moderate |
| Hypoglycaemia | 5/743 | 0/590 | 0 | 3.64 (0.65, 20.37) | No | Moderate |